MD-110 Phase 3 Study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080225134

Enrollment

100

Registered

2020-03-19

Start date

2020-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemotherapy-induced febrile neutropenia

Interventions

investigational material(s) Generic name etc : MD-110 INN of investigational material : - Therapeutic category code : 339 Other agents relating to blood and body fluides Dosage and Administration for

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Diagnosed with primary invasive breast cancer, etc.

Exclusion criteria

Exclusion criteria: Double cancer, etc.

Design outcomes

Primary

Measure	Time frame
safety efficacy Efficacy: The duration of severe neutropenia (DSN) Safety: Adverse Reactions	—

Secondary

Measure	Time frame
efficacy The rate of febrile neutropenia (FN)	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026